Fulcrum Therapeutics, Inc. Common Stock (FULC) Stock Price

FULCStock

$3.85−42.11%52W

Market Cap$293.74M

P/E—

PEG Ratio—

Div yield—

Beta2.63

FULC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-67.06%

Price vs S&P 500 (4W)2.23%

VGM Score48.49

Book Value / Share (Quarterly)$4.07

P/TBV (Annual)1.29x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)61.03%

Cash Flow / Share (Quarterly)$-0.87

Price vs S&P 500 (YTD)-78.78%

Net Profit Margin (TTM)8.13%

EPS (TTM)$-0.90

10-Day Avg Trading Volume2.18M

EPS Excl Extra (TTM)$-0.90

EPS (Annual)$-1.18

ROI (Annual)-21.46%

Net Profit Margin (5Y Avg)-1288.02%

Cash / Share (Quarterly)$4.18

ROA (Last FY)-20.44%

EBITD / Share (TTM)$-0.99

ROE (5Y Avg)-32.06%

Operating Margin (TTM)-3.60%

Cash Flow / Share (Annual)$-0.91

P/B Ratio0.91x

P/B Ratio (Quarterly)0.78x

Net Income / Employee (Annual)$-1,361,500

EV / Revenue (TTM)2.87x

ROA (TTM)-21.19%

EPS Incl Extra (Annual)$-1.18

Current Ratio (Annual)27.40x

Quick Ratio (Quarterly)31.16x

3-Month Avg Trading Volume2.20M

52-Week Price Return-42.11%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.13

P/S Ratio (Annual)3.53x

Asset Turnover (Annual)0.31x

52-Week High$15.74

Operating Margin (5Y Avg)-1396.58%

EPS Excl Extra (Annual)$-1.18

CapEx CAGR (5Y)-25.19%

Tangible BV CAGR (5Y)172.58%

26-Week Price Return-55.13%

Quick Ratio (Annual)27.08x

13-Week Price Return-43.55%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)31.35x

Enterprise Value$234.22M

Asset Turnover (TTM)0.29x

Book Value / Share Growth (5Y)8.97%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-12.16%

Cash / Share (Annual)$5.29

3-Month Return Std Dev110.73%

Net Income / Employee (TTM)$-1,040,500

ROE (Last FY)-21.46%

EPS Basic Excl Extra (Annual)$-1.18

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.90

Receivables Turnover (Annual)0.00x

ROI (TTM)-22.54%

P/S Ratio (TTM)3.46x

Pretax Margin (5Y Avg)-1288.02%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.82

Price vs S&P 500 (52W)-60.66%

Year-to-Date Return-65.96%

5-Day Price Return0.26%

EPS Normalized (Annual)$-1.18

ROA (5Y Avg)-28.96%

Net Profit Margin (Annual)-12.16%

Month-to-Date Return7.54%

Cash Flow / Share (TTM)$-1.64

EBITD / Share (Annual)$-1.32

Operating Margin (Annual)-27.37%

ROI (5Y Avg)-32.06%

EPS Basic Excl Extra (TTM)$-0.90

P/TBV (Quarterly)1.00x

P/B Ratio (Annual)2.14x

Pretax Margin (TTM)8.13%

Book Value / Share (Annual)$5.24

Price vs S&P 500 (13W)-45.50%

Beta2.63x

Revenue / Share (TTM)$0.00

ROE (TTM)-22.54%

52-Week Low$2.83

vGradeB

mGradeD

vgmGradeC

FULC Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 30, 2026	-$0.22	-$0.22	+1.68%(+$0.00)
Q1 2026	Apr 27, 2026	-$0.30	-$0.25	+16.84%(+$0.05)
Q4 2025	Feb 24, 2026	-$0.30	-$0.31	-2.31%(-$0.01)
Q3 2025	Oct 29, 2025	-$0.29	-$0.31	-5.53%(-$0.02)
Q2 2025	Jul 29, 2025	-$0.29	-$0.28	+3.45%(+$0.01)

FULC Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.06

2.38

2.42

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
FULCFulcrum Therapeutics, Inc. Common Stock	B	—	D	$3.85
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Fulcrum Therapeutics, Inc. Common Stock

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for genetically defined rare diseases. Its lead candidate, Pociredir, is an oral drug designed to induce fetal hemoglobin in patients with sickle cell disease; Phase 1b data demonstrated clinically meaningful HbF induction and improvements in hemolysis and anemia markers. The company maintains a pipeline of additional clinical and preclinical programs targeting the root causes of rare genetic disorders.